BELVIN MARCIA — SEC Form 4 filings
SEC reporting owner CIK 1970752. 10 Form 4 filings on record with FilingPulse; latest filed 2026-03-19.
Transaction summary — filings shown
Covers all 10 filings on record, filed 2024-01-19 to 2026-03-19. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 5 legs across 5 filings — 81,864 shares, $283,118 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 19.
- Largest priced transaction: sale of 31,492 shares @ $6.42 ($202,273) in CytomX Therapeutics, Inc., filed 2026-03-19.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | SVP, Chief Scientific Officer | 10 | — | 5 legs · 81,864 sh · $283,118 | 19 |
Form 4 filings — BELVIN MARCIA
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-03-19 | 4 | CytomX Therapeutics, Inc. (CTMX) | Sale (S): 31,492 @ $6.42 | EDGAR |
| 2026-02-04 | 4 | CytomX Therapeutics, Inc. (CTMX) | Grant/award (A): 60,000 @ $0 · Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2025-09-30 | 4 | CytomX Therapeutics, Inc. (CTMX) | Grant/award (A): 36,300 (derivative) @ $0 · Grant/award (A): 18,150 (derivative) @ $0 | EDGAR |
| 2025-06-17 | 4 | CytomX Therapeutics, Inc. (CTMX) | Option exercise (M): 37,500 @ $0 · Sale (S): 13,884 @ $2.69 · Option exercise (M): 37,500 (derivative) @ $0 | EDGAR |
| 2025-03-20 | 4 | CytomX Therapeutics, Inc. (CTMX) | Sale (S): 19,512 @ $0.60 | EDGAR |
| 2025-02-10 | 4/A | CytomX Therapeutics, Inc. (CTMX) | Grant/award (A): 35,000 @ $0 · Grant/award (A): 57,500 @ $0 · Grant/award (A): 150,000 (derivative) @ $0 · Grant/award (A): 115,000 (derivative) @ $0 | EDGAR |
| 2025-02-06 | 4 | CytomX Therapeutics, Inc. (CTMX) | Grant/award (A): 30,000 @ $0 · Grant/award (A): 57,500 @ $0 · Grant/award (A): 140,000 (derivative) @ $0 · Grant/award (A): 115,000 (derivative) @ $0 | EDGAR |
| 2024-08-22 | 4 | CytomX Therapeutics, Inc. (CTMX) | Option exercise (M): 11,250 @ $0 · Sale (S): 4,181 @ $1.23 · Option exercise (M): 11,250 (derivative) @ $0 | EDGAR |
| 2024-03-21 | 4 | CytomX Therapeutics, Inc. (CTMX) | Sale (S): 12,795 @ $2.09 | EDGAR |
| 2024-01-19 | 4 | CytomX Therapeutics, Inc. (CTMX) | Grant/award (A): 26,250 @ $0 · Grant/award (A): 122,500 (derivative) @ $0 · Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1970752 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →